Therapist training
Therapists in training (February 2020) - COMPASS therapist training programme
Our therapist training programme
Our therapist training programme has been designed by leading experts from the fields of psychology, psychiatry and psychedelic therapy research. It is currently being used to train therapists taking part in our phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, as approved by the US Food and Drug Administration (FDA), as part of our Investigational New Drug Application (IND).
All our therapists must be registered mental health professionals. They are typically mental health nurses, clinical psychologists, or psychiatrists with experience in counselling or psychotherapy. Therapists are chosen based on core qualities of compassion, openness, presence, and motivation to help patients.
Our core training curriculum consists of:
-
10+ hours
of self-paced online learning through our Shared Knowledge Platform
-
Five days
of interactive learning, focussing on role-play and feedback, led by our dedicated trainers
-
Clinical training while supporting participants in at least four psilocybin research sessions, under the guidance of experienced therapists, at partner academic institutions
-
Continuous professional development through ongoing mentoring, clinical supervision, and monthly webinars
We have completed our current phase of therapist training. If you are interested in signing up for our next phase of training, please send your CV and a statement of interest to Jess Rose Stuart (Europe) or Batya Septimus (North America).